- Home
- QXO vs LEGN Comparison
QXO vs LEGN Comparison
Compare QXO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QXO
- LEGN
- Stock Information
- Founded
- QXO 1988
- LEGN 2014
- Country
- QXO United States
- LEGN United States
- Employees
- QXO N/A
- LEGN N/A
- Industry
- QXO EDP Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- QXO Technology
- LEGN Health Care
- Exchange
- QXO Nasdaq
- LEGN Nasdaq
- Market Cap
- QXO 5.7B
- LEGN 5.4B
- IPO Year
- QXO N/A
- LEGN 2020
- Fundamental
- Price
- QXO $22.55
- LEGN $34.89
- Analyst Decision
- QXO Buy
- LEGN Strong Buy
- Analyst Count
- QXO 3
- LEGN 12
- Target Price
- QXO $34.33
- LEGN $77.09
- AVG Volume (30 Days)
- QXO 8.9M
- LEGN 2.1M
- Earning Date
- QXO 05-08-2025
- LEGN 08-08-2025
- Dividend Yield
- QXO 129.94%
- LEGN N/A
- EPS Growth
- QXO N/A
- LEGN N/A
- EPS
- QXO N/A
- LEGN N/A
- Revenue
- QXO $55,945,000.00
- LEGN $728,303,000.00
- Revenue This Year
- QXO $4,438.18
- LEGN $65.17
- Revenue Next Year
- QXO $317.09
- LEGN $53.86
- P/E Ratio
- QXO N/A
- LEGN N/A
- Revenue Growth
- QXO 0.21
- LEGN 112.46
- 52 Week Low
- QXO $10.61
- LEGN $27.34
- 52 Week High
- QXO $157.28
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- QXO 78.60
- LEGN 56.69
- Support Level
- QXO $19.30
- LEGN $33.84
- Resistance Level
- QXO $20.73
- LEGN $39.36
- Average True Range (ATR)
- QXO 0.98
- LEGN 1.87
- MACD
- QXO 0.25
- LEGN 0.44
- Stochastic Oscillator
- QXO 86.82
- LEGN 60.72
About QXO QXO Inc. Common Stock
QXO Inc provides technology solutions, primarily to clients in the manufacturing, distribution, and service sectors. It provides consulting and professional services, specialized programming, training, and technical support. It also offers solutions for accounting, financial reporting, enterprise resource planning, warehouse management systems, customer relationship management, business intelligence, and other applications.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.